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Kidney Transplant Recipients
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Abstract
Antibody mediated rejection (ABMR) presents a significant challenge for 
long term graft survival in kidney transplantation. New technologies, includ-
ing genomic studies and assays to detect and define donor-specific antibodies, 
have provided important insights into the pathophysiology and diagnosis of 
ABMR. Unfortunately, this progress has not yet translated into better outcomes for 
patients, as in the absence of a drug able to suppress antibody generation by plasma 
cells, available therapies can only slow down graft destruction. This chapter reviews 
the current understanding of ABMR, and details its diagnosis, and treatments, both 
those established in current routine clinical practice and those on the horizon.
Keywords: antibody mediated rejection, humoral rejection, kidney rejection, kidney 
transplantation, kidney transplant rejection, donor specific antibodies
1. Introduction
Antibody-mediated rejection (ABMR), also termed humoral rejection, is one 
of the most important causes of allograft dysfunction and loss accounting for up 
to 76% of death-censored graft failures beyond the first year of transplantation 
[1, 2]. According to current evidence, B cell and plasma cell activation results 
in the generation of donor-specific antibodies (DSAs), which bind to human 
leukocyte antigen (HLA) or non-HLA molecules expressed on endothelial cells 
within the renal allograft [3].
ABMR often represents a pathological spectrum that co-exists with T-cell-
mediated rejection [3]. Active (acute) ABMR is characterized by serological 
evidence of DSA, peritubular capillaritis, glomerulitis, cellular necrosis, thrombotic 
microangiopathy, and a relatively rapid decline in allograft function. The response 
to currently available therapies is often favorable. Chronic ABMR, on the other 
hand, is characterized by transplant glomerulopathy, a distinct pathophysiological 
process resulting from a repetitive pattern of thrombotic events and inflamma-
tory changes that lead to endothelial cell injury and allograft matrix remodeling. 
It usually results in a slow and progressive decline in renal function, unlikely to be 
reversed by current therapeutic strategies [3, 4].
2. Pathogenesis
In the 1960 Kissmeyer et al. [5] were the first to observe the deleterious 
impact of allo-antibodies in kidney grafts. Since then great advances have 
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occurred in solid organ transplantation. Nowadays, it is believed that immuno-
logic reactions associated with ABMR can be triggered by circulating antibodies 
against donor HLA, non-HLA or ABO antigens, i.e. donor specific antibodies 
(DSAs) [6].
DSAs are most commonly directed against human leukocyte antigen (HLA)/
major-histocompatibility-complex (MHC) class I and II antigens [7]. HLA class 
I antigens are expressed on all nucleated cells, whereas HLA class II antigens are 
restricted to antigen-presenting cells (B lymphocytes, dendritic cells) and endo-
thelial cells [8]. In addition to DSAs existing prior to transplant due to recipient 
sensitization (pregnancy, blood transfusions, and previous transplantation), it has 
been realized that they can emerge at any time after transplant, thus mediating 
allograft injury [9, 10]. These de novo DSAs are different in their pathogenicity. 
Those directed against class II HLA are associated with a worse prognosis than 
DSAs against class I HLA [10].
However, the antibodies can also be directed against other donor specific antigens 
such as MHC-class I-related chain A (MICA) antigens, MHC-class I-related chain 
B (MICB) antigens, platelet-specific antigens, molecules of the renin-angiotensin 
pathway, and polymorphisms involving chemokines and their receptors [11–13]. 
MICA antigens are expressed on endothelial cells, dendritic cells, fibroblasts, epithe-
lial cells, and many tumors, but not on peripheral-blood lymphocytes [12].
The major mechanism involved in antibody-mediated kidney injury is activation 
of the classical complement pathway by the binding of DSA to HLA and subsequent 
binding of the C1 complex, which ultimately leads to formation of the membrane 
attack complex (C5b-C9) (Figure 1) [14, 15].
This leads to activation of polymorphonuclear inflammatory cells, NK 
cell and monocyte recruitment and inflammation, as well as activation of the 
coagulation cascade, which in turn leads to widespread microvascular injury 
evident as peritubular capillaritis, glomerulitis and microvascular thrombosis. 
B-cell responses against MHC antigens are T-cell dependent and require the 
involvement of antigen-presenting cells and costimulatory molecules such as 
CD40 ligand or soluble interleukins. These responses take 2–3 weeks to develop 
and lead to immunologic memory, allowing a more efficient antibody response 
upon repeat stimulation. Eventually transplant glomerulopathy develops 
(chronic phase) due to recurrent injury and repair with glomerular basement 
Figure 1. 
Activation of classical complement pathway in ABMR in renal transplant recipients. Following binding of 
DSA to the vascular endothelium of kidney allograft, the C1 complex activates the serine esterases C1s and C1r, 
resulting in the cleavage of C4, deposition of C4d, and the assembly of the classical pathway C3 convertase. 
C3 convertase cleaves C3 into C3a, a potent pro-inflammatory mediator, and C3b, which propagates the 
complement cascade and leads to the formation of the pro-inflammatory mediator C5a and the membrane 
attack complex (C5b-C9). For more details, see Stegall et al. [15] ABMR-antibody-mediated rejection; DSA-
donor-specific antibody; HLA-human leukocyte antigen.
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membrane remodeling, mesangial matrix expansion, capillary obliteration, foot 
process effacement [15]. Microcirculation remodeling at the level of peritu-
bular capillaries progresses to interstitial fibrosis and tubular atrophy causing 
allograft failure.
3. Diagnostic criteria for antibody mediated rejection
3.1 Histopathological features
By light microscopy, active antibody mediated rejection is characterized by 3 
types of tissue injury: acute tubular injury, microcirculation inflammation with 
neutrophils and mononuclear cells in glomeruli and peritubular capillaries, and 
fibrinoid necrosis of arteries (Figure 2) [14].
Acute tubular injury includes loss of brush borders, thinning of tubular 
epithelial cells cytoplasm, shedding of tubular epithelium, and focal loss of nuclei 
(Figure 3). Focal necrosis of tubules can be found in minority of cases. In addi-
tion to oedema without significant interstitial infiltrate, proximal tubules express 
HLA-DR (Figure 4). Microcirculation inflammation with neutrophils and mono-
nuclear cells in glomeruli and peritubular capillaries appears as glomerulitis and 
peritubular capillaritis. Glomerular capillaries are dilated and filled with swollen 
endothelial cells and inflammatory cells (Figure 5). In severe cases, glomerular 
capillary thrombosis can be detected (Figure 6). In glomerular injury due to 
ABMR usually predominates macrophages which express CD68 and neutrophils.
Figure 2. 
Features of active antibody mediated rejection: Acute tubular injury [(A) hematoxylin-eosin stain (HE), 
200×], microcirculation inflammation with neutrophils and mononuclear cells in glomeruli-glomerulitis [(B) 
HE, 400×] and peritubular capillaries-peritubular capillaritis [(C) HE, 200×], and fibrinoid necrosis of 
artery [(D) HE, 200×].
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Figure 3. 
Acute tubular injury/necrosis accompanied by interstitial edema in active antibody mediated rejection [(A) 
periodic-acid Schiff (PAS), 100×]. Acute tubular injury/necrosis and glomerular capillary necrosis [(B) HE, 100×].
Figure 4. 
Diffuse HLA-DR positivity in proximal tubules in active antibody mediated rejection (immunohistochemistry, 
HLA-DR, 100×).
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Figure 5. 
Focal glomerulitis in active antibody mediated rejection-Banff score g3. Dilated glomerular capillaries are 
filled with swollen endothelial cells and inflammatory cells (PAS, 200×).
Figure 6. 
Glomerular capillary thrombosis [(A) HE, 400×)] and fibrinoid necrosis of hilar arteriole [(B) trichrome 
stain, 200×)] in severe active antibody mediated rejection.
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Cortical peritubular capillaries are dilated and filled with numerous inflam-
matory cells and sometimes focal interstitial hemorrhages are found (Figure 7). 
Presence of neutrophils in dilated peritubular capillaries may be associated with 
class I DSA and hyperacute rejection. Immunohistochemistry and immunofluores-
cence revealed diffuse linear positivity of C4d along peritubular capillaries in the 
Figure 7. 
Diffuse peritubular capillaritis in active antibody mediated rejection-Banff score ptc3 [(A and B) HE and 
immunohistochemistry, C4d, 200×)]. Neutrophils in peritubular capillaries in severe active antibody mediated 
rejection [(C) HE, 400×].
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cortex and medulla (Figure 8). Dilated vascular spaces in the area between cortex 
and medulla should not be assessed as peritubular capillaritis, since those vascular 
spaces represent increased turnover between cortex and medulla not related to 
Figure 8. 
Diffuse C4d positivity in active antibody mediated rejection (Banff score C4d 3) by immunofluorescence [(A) 
200×] and immunohistochemistry [(B) 200×].
Figure 9. 
Fibrinoid necrosis in small interlobular artery-Banff score v3 in severe active antibody mediated rejection 
(arrow). Glomerular capillary thrombosis and acute tubular necrosis are also seen (HE, 200×).
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rejection. Interstitial oedema and hemorrhage may be prominent. B cells can be 
found in aggregates, and plasma cells can be detected, but interstitial infiltrate does 
not fulfill criteria for T-cell mediated rejection.
Figure 11. 
Acute vascular thrombotic microangiopathy in active antibody mediated rejection [(A) HE, 200×].  
Chronic glomerular and vascular thrombotic microangiopathy in chronic active antibody mediated rejection 
[(B) Weigert stain (W), 100×].
Figure 10. 
Chronic active vascular rejection with intimal endarteritis and intimal fibrosis. HE, 200×.
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In about 25% of cases with ABMR, small interlobular arteries show myocyte 
necrosis, fragmentation of elastica, and accumulation of eosinophilic material 
termed fibrinoid necrosis (Figure 9). There is usually only scant mononuclear 
infiltrate in the intima and adventitia. Some arteries may show transmural 
arterial inflammation without fibrinoid necrosis reminiscent of T-cell medi-
ated vascular rejection (Figure 10). Whether the cellular component of 
Figure 12. 
Chronic burn out vascular rejection without intimal infiltrate in arcuate artery-Banff score cv3 [(A) HE, 
100×]. Intimal fibrosis due to chronic rejection is superimposed on fibroelastic lamelation associated with 
arterial hypertension [(B) W, 100×]. Artery with elastic duplication due to arterial hypertension without 
rejection [(C) W, 100×].
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transplant endarteritis in ABMR is different from that due to T-cell mediated 
rejection is not apparent. Arterial thrombosis is uncommon. However, acute 
ABMR may also manifest as TMA affecting glomerular and vascular endothe-
lium (Figure 11). TMA is characterized by bloodless glomeruli with swollen 
endothelium and mucoid intimal thickening and trapped red cells in the 
vessel walls.
Over time, active ABMR usually transform to chronic ABMR with different 
levels of activity. Arterial lesions progress to intimal fibrosis with neomedia 
formation and progressive narrowing of vascular lumen (Figure 12) leading to 
chronic transplant changes—widespread interstitial fibrosis and tubular atrophy. 
In addition, chronic microvasculature changes appeared, including glomerular 
and peritubular capillaries. At the beginning, chronic glomerular lesions are 
visible only by EM as neolamina in glomerular capillary loops (Figure 13), which 
may progress to double contour formation and mesangial interposition seen 
by light microscopy (Figure 14). Peritubular capillaries electron micrograph 
revealed basement membrane multilamelation consistent with chronic ABMR 
(Figure 15) [14].
Figure 13. 
Swollen endothelial cells in early glomerular thrombotic microangiopathy due to severe active antibody 
mediated rejection. Glomerular basement membrane appears normal (A). Subendothelial widening with 
oedema and neolamina formation in early chronic active antibody mediated rejection seen only by electron 
microscopy-Banff score cg1a [(B), all electron micrographs].
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3.2 Classification of antibody mediated rejection
According to Banff 2017 two types of ABMR were proposed-active ABMR 
(previously referred as acute ABMR) and chronic active ABMR [16].
The 2017 Banff meeting report noted the confusion generated by reports on 
acute and chronic ABMR, and emphasized the importance of correctly defining 
ABMR, including additional characteristics, like the nature of the antibody; the 
significance of C4d; the severity of microcapillary injury, gene transcripts, molecu-
lar and cellular signatures. As the previously used term acute ABMR was found to 
be misleading by the majority of the working group, the term active was elected to 
simply refer to lesions of ABMR with microvascular injury and evidence of current 
or recent antibody interaction with graft endothelium but without morphologic evi-
dence of chronic vascular injury (transplant glomerulopathy, peritubular capillary 
basement membrane multilayering, new-onset arterial intimal fibrosis).
Two principal phenotypes defined in association of previously termed acute 
ABMR((1) ABMR phenotype 1 in the presensitized patient, occurring early post-
transplant; and (2) ABMR phenotype 2, which develops from the emergence of 
Figure 14. 
Double contour formation in glomerulus with chronic glomerulitis in chronic active antibody mediated 
rejection-Banff score cg3 [(A) Jones, 400×] and normal glomerulus [(B) Jones, 400×]. Glomerulitis in chronic 
active antibody mediated rejection (Banff score g3, cg3) with diffuse double contour formation (glomerular 
capillaries with double contours are filled with swollen endothelial cells and inflammatory cells, among them 
macrophages predominate (CD68 and PAS, ×400).
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According to revised Banff 2017 classification of antibody-mediated rejection (ABMR) in renal allografts 
antibody-mediated changes are classified in Category 2, consisting of:
Active ABMR; all 3 criteria must be met for diagnosis
1. Histologic evidence of acute tissue injury, including 1 or more of the following:
• Microvascular inflammation (g > 0 and/or ptc > 0), in the absence of recurrent or de novo glomeru-
lonephritis, although in the presence of acute TCMR, borderline infiltrate, or infection, ptc ≥ 1 alone 
is not sufficient and g must be ≥1
• Intimal or transmural arteritis (v > 0)
• Acute thrombotic microangiopathy, in the absence of any other cause
• Acute tubular injury, in the absence of any other apparent cause
2. Evidence of current/recent antibody interaction with vascular endothelium, including 1 or more of the 
following:
• Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d > 0 by 
IHC on paraffin sections)
• At least moderate microvascular inflammation ([g + ptc] ≥2) in the absence of recurrent or de novo 
glomerulonephritis, although in the presence of acute TCMR, borderline infiltrate, or infection, 
ptc ≥ 2 alone is not sufficient and g must be ≥1
• Increased expression of gene transcripts/classifiers in the biopsy tissue strongly associated with 
ABMR, if thoroughly validated
3. Serologic evidence of donor-specific antibodies (DSA to HLA or other antigens). C4d staining or 
expression of validated transcripts/classifiers as noted above in criterion 2 may substitute for DSA; 
however thorough DSA testing, including testing for non-HLA antibodies if HLA antibody testing is 
negative, is strongly advised whenever criteria 1 and 2 are met.
Figure 15. 
Chronic active antibody mediated rejection: mild basement membrane multilamelation with swollen 
endothelium (A) and significant basement membrane multilamelation (B, D). Normal peritubular capillary 
(C, all electron micrographs).
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de novo DSA in the late posttransplant period and is thought to be mostly related to 
nonadherence or inadequate immunosuppression) are not positioned in Banff 2017 
classification.
In accordance with major advances in molecular biology and gene rearrange-
ment, the diagnosis of ABMR is now dependent on histologic, serologic and 
transcriptomics findings (see Table 1) [16]. For detailed scoring explanations of 
histological lesions for antibody mediated rejection according to Banff 2017, please 
see Table 2.
Chronic active ABMR; all 3 criteria must be met for diagnosis
4. Morphologic evidence of chronic tissue injury, including 1 or more of the following:
• Transplant glomerulopathy (cg > 0) if no evidence of chronic TMA or chronic recurrent/de novo 
glomerulonephritis; includes changes evident by electron microscopy (EM) alone (cg1a)
• Severe peritubular capillary basement membrane multilayering (requires EM)
• Arterial intimal fibrosis of new onset, excluding other causes; leukocytes within the sclerotic intima 
favor chronic ABMR if there is no prior history of TCMR, but are not required
5. Identical to criterion 2 for active ABMR, above
6. Identical to criterion 3 for active ABMR, above, including strong recommendation for DSA testing 
whenever criteria 1 and 2 are met
C4d staining without evidence of rejection; all 4 features must be present for diagnosis
7. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d > 0 by 
IHC on paraffin sections)
8. Criterion 1 for active or chronic, active ABMR not met
9. No molecular evidence for ABMR as in criterion 2 for active and chronic, active ABMR
10. No acute or chronic active TCMR, or borderline changes
Table 1. 
Classification of antibody mediated rejection according to Banff 2017 [16].
Banff scoring for antibody mediated rejection
v—vascular inflammation: the most severely affected 
artery dictates the score; an asterisk is added to the v 
score if interstitial hemorrhage or infarct present
v0: no arteritis
v1: intimal arteritis with <25% luminal area lost 
(minimum = 1 cell, 1 artery)
v2: intimal arteritis with ≥25% of luminal area lost 
in 1+ arteries
v3: transmural arteritis or fibrinoid necrosis 
(medial smooth muscle necrosis) with lymphocyte 
infiltrate in vessels
g—glomerulitis: percentage of glomerular capillaries 
partially or completely occluded by inflammatory 
cells (polymorphonuclear leucocytes and 
mononuclear cells) and endothelial cell enlargement
g0: no glomerulitis
g1: <25% of glomeruli involved (mostly segmental)
g2: 25–75% of glomeruli involved (segmental to 
global)
g3: >75% of glomeruli involved (mostly global)
ptc—peritubular capillaritis: the most severely 
affected peritubular capillary (PTC) dictates 
the score; an asterisk is added to the ptc score if 
neutrophils are lacking/only mononuclear cells are 
present
ptc0: <3 cells/PTC
ptc1: 1+ inflammatory cells in >10% of cortical 
PTCs with 3–4 cells in most severely involved PTC
ptc2: 1+ inflammatory cells in >10% of cortical 
PTCs with 5–10 cells in most severely involved PTC
ptc3: 1+ inflammatory cells in >10% of cortical 
PTCs with >10 cells in most severely involved PTC
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3.3 Essential differences in comparison to previous classification
3.3.1 C4d in antibody mediated rejection
C4d is a split product of C4 activation and has no known biological action. It 
may be activated by the classical and lectin complement pathways. C4d staining is 
a specific marker of ABMR when the stain is deposited in the capillaries of kidney 
allograft and is now considered an alternative for DSA criterion in cases where DSA 
testing is not available or potentially false negative [17–19]. However, C4d staining 
has been shown to have significant limitations for diagnosis of ABMR due to low 
sensitivity, with negative results in up to 50% of patients with antibody-mediated 
rejection [4, 20]. Furthermore, C4d positivity has been reported in the absence of 
other evidence of graft injury as its expression depends on the density of PTCs and 
also may not be associated with measurable DSA in the case of non-HLA antibod-
ies or antibodies absorbed by the allograft [21]. In studies comparing the risk of 
allograft loss among patients with consistently C4d negative ABMR vs. patients 
with C4d positive ABMR at a single center, both phenotypes were associated with 
statistically comparable increased graft loss compared with ABMR free matched 
controls. No clinical characteristics that reliably differentiated C4d negative and 
C4d positive ABMR were identified [22].
3.3.2  Expression of endothelium associated transcripts (ENDATs) in antibody 
mediated rejection
In patients with negative C4d staining, the diagnosis of ABMR may be con-
firmed on the basis of increased expression of gene transcripts or classifiers in the 
biopsy tissue that are strongly associated with ABMR [16].
Molecular markers associated with endothelial injury were first introduced into 
criteria of the ABMR classification in Banff 2013 [23]. Since that time, combina-
tions of transcripts have been introduced and ABMR specific sets of transcripts 
proposed by different authors [16]. Data from Loupy et al. [4] showed that adding 
Banff scoring for antibody mediated rejection
C4d—percentage of PTC (or vasa recta in the 
medulla) that has linear circumferential staining, 
scored in at least 5 high powered fields of cortex or 
medulla without scarring or infarct
C4d0: no staining of PTC and medullary vasa recta
C4d1: <10% of PTC and medullary vasa recta
C4d2: 10–50% of PTC and medullary vasa recta
C4d3: >50% of PTC and medullary vasa recta
cg—transplant glomerulopathy: percentage of 
glomerular capillary loops with duplication of 
glomerular basement membrane in most affected 
nonsclerotic glomerulus
cg0: none by light microscopy (LM) and electron 
microscopy
cg1a: only by electron microscopy in 3 glomerular 
capillaries
cg1b: ≤25% by LM (1+ glomerular capillaries with 
glomerular basement membrane double contours 
by LM)
cg2: 26–50% by LM
cg3: >50% by LM
cv—transplant arteriopathy: arterial fibrointimal 
thickening; percentage of narrowing of lumen of 
most severely affected artery
cv0: none
cv1: ≤25% of the luminal area
cv2: 26–50% of the luminal area
cv3: >50% of the luminal area
Table 2. 
Detailed scoring explanations of histological lesions for antibody mediated rejection according to Banff 2017 [16].
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the results of the ABMR classifier to histologic findings significantly improved their 
ability to diagnose ABMR, independently from C4d and DSA.
However, it should be noted that at this point no specific Banff recommenda-
tions are given regarding which molecular transcript sets should be tested to assess 
gene expression. This includes the decision whether to perform molecular studies 
on freshly sampled tissue or FFPE. An advanced molecular approach using machine 
learning and classifiers has been done in recent years and has provided valuable 
information for improvement of rejection assessment [24]. The Alberta Transplant 
Applied Genomics Center team at the University of Alberta developed a “molecular 
microscope” approach to kidney transplant biopsies and has provided a system for 
distinguishing ABMR from other allograft pathologies by the expression of activated 
ENDATs. They proposed new rules to integrate molecular tests and histology into a 
precise diagnostic system that can reduce errors, ambiguity, and inter-pathologist 
disagreement [25].
4. Clinical features
In clinical setting ABMR can present as hyperacute (occurring within minutes 
after the vascular anastomosis), acute (occurring days to weeks after transplanta-
tion), late acute (occurring 3 months after transplantation), or chronic (occurring 
months to years after transplantation) [26–28].
4.1 Acute antibody mediated rejection
Acute ABMR almost always presents with an increase in serum creatinine, which 
is sometimes severe and accompanied with oligo-/anuria necessitating dialysis 
treatment. It is usually seen during the first few weeks after transplantation but can 
occur later, in which case it is usually associated with decreased immunosuppression 
or noncompliance [29]. The incidence varies with the amount of DSA present at the 
time of transplantation. In patients with high levels of DSA (i.e. sufficient to cause 
strongly positive crossmatch) the incidence may be as high as 40% in the first month 
after transplantation, while the incidence is less than 10% in patients with a negative 
crossmatch and DSA demonstrated only by solid phase assay [30, 31] According to 
Banff 2017 scoring system [16], histopathology in these patients is related to charac-
teristics of active ABMR.
4.2 Chronic antibody mediated rejection
The diagnosis of chronic humoral rejection is usually, but not always, made in 
patients who are more than 6 months post transplantation [32]. The rise in serum cre-
atinine is usually gradual and often accompanied by stepwise increase of proteinuria. 
Patients with chronic rejection are often hypertensive, sometimes nephrotic range pro-
teinuria or even nephrotic syndrome can be observed. However, patients often have no 
clinical symptoms associated with chronic rejection, unless renal function is decreased 
enough that the patient has signs and symptoms of uremia. Except for proteinuria, 
urinalysis is usually unremarkable in chronic rejection. Contrary, in rare instances 
progression can be fairly rapid, especially with ongoing active lesions (chronic active 
ABMR), resulting in graft failure within months [33]. Chronic allograft injury is 
characteristically seen as transplant glomerulopathy on kidney biopsies. In addition to 
chronic features, signs of activity are often present, with prominent mononuclear cells 
in capillary loops with endothelial swelling (transplant glomerulitis) [34].
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4.3 Subclinical antibody mediated rejection
A certain amount of kidney transplant recipients present with stable kidney graft 
function, but histological evidence of smoldering active ABMR on protocol biopsies 
[35]. These patients often have low-level DSAs (de novo or persistent/recurrent). 
Evidence suggests that untreated subclinical ABMR is an important predictor of poor 
renal allograft outcomes [36]. However, the lack of long-term follow-up data has pre-
vented the development of strong guidelines for effective therapeutic interventions.
4.4 Hyperacute antibody mediated rejection
Nowadays, hyperacute rejection is a rare event in kidney transplantation affect-
ing mostly presensitized patients (previous transplantation, blood transfusions, or 
pregnancy) [37]. It occurs due to preformed DSA present in high titers and presents 
as graft failure that can occur within minutes (but sometimes may be delayed 
for a few days) after transplantation [38]. The occurrence of this type of rejec-
tion is extremely rare, as preformed antibodies can usually be excluded by CDC 
crossmatch. However, there is growing evidence that there may exist hyperacute 
rejections mediated by endothelial, non-HLA antibodies that cannot be detected in 
standard T and B lymphocyte crossmatch techniques [39].
5. Treatment
Treatment for ABMR is not standardized, and there is still no evidence-based 
treatment guidelines. A recent therapy of ABMR in renal allografts is systematically 
reviewed by Wan et al. [2]. In addition to plasma exchange and intravenous immu-
noglobulin, which still present a backbone of treatment, a number of other therapies 
have been tried in small studies without consistent benefit, including anti-CD20, 
proteasome inhibitors, complement inhibitors, anti-interleukin-6 receptor blockers, 
and immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS).
5.1 IVIG
Intravenous immunoglobulin (IVIG) is used for treatment of ABMR, and it is 
used as an element of desensitizing protocols for ABO- and HLA-incompatible renal 
transplantation [40].
IVIG is prepared by human plasma from approximately 50,000–100,000 
of healthy donors, composed of 90% intact IgG, a few dimers, Fabs (fragment 
antigen-binding) and traces of IgM and IgA [41].
There are many postulated immunomodulatory mechanisms of 
IVIG. Investigations in the early 1990s suggested the therapeutic potential of IVIG 
was due primarily to anti-idiotypic interactions with HLA antibodies [42]. Apart 
from its effects on B cells and phagocytes via Fc-gamma receptors, IVIG also func-
tions as a scavenger of activated complement [43, 44].
Two general treatment protocols have been developed utilizing IVIG. The first 
is the use of high dose IVIG (2 g/kg) alone and the second is to combine lower dose 
IVIG with other modalities, usually plasmapheresis [45]. After the first successful 
report of Jordan et al. in 1998 [46] who treated acute ABMR in kidney and heart 
allografts by high-dose IVIG and methylprednisolone, there were more studies with 
usage of IVIG alone or in combination with plasmapheresis to show effectiveness in 
treatment of ABMR [47, 48].
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Additional benefit of IVIG is its ability to replenish gamma globulin lost during 
therapeutic apheresis, decreasing infection risk [49].
5.2 Plasmapheresis
Both immunoabsorption (IA) and plasmapheresis (PP) are known to lower 
HLA-specific antibody levels in a variety of clinical settings [49]. Despite the sub-
stantial reductions in the titer of donor-specific anti-HLA antibodies achieved by IA 
and PP, the graft survival in these patients is significantly reduced, due to rebound 
synthesis of de novo alloantibodies.
PP is the most frequent modality applied and generally involves 1.0–1.5 
volume exchange, using albumin as replacement. It is usually performed daily 
or every other day for an average of six sessions (up to 14 days). The initial 
treatment is typically a one-and-one-half-volume exchange with albumin, 
and subsequent treatments are a one-volume exchange with albumin. To avoid 
fresh frozen plasma administration, most clinicians prefer an every-other-day 
PP schedule as albumin alone can often be administered for replacement with 
interval recovery of the prothrombin time, partial thromboplastin time, and 
fibrinogen to acceptable levels. This avoids the risk of antigen sensitization. IA is 
a more selective modality that uses adsorbent membranes for antibody elimina-
tion [49, 50].
Few studies have been published where PP modalities are the sole or primary 
form of antibody reducing therapy [51–54]. However, PP alone has limited success 
in the treatment of ABMR, and this finding has led to the addition of therapies 
to prevent immunoglobulin resynthesis and B-cell proliferation. Therefore, PP 
is often used in combination with other antibody blocking (IVIG), suppression 
(rituximab, mycophenolate, calcineurin inhibitors), or depleting (bortezomib) 
modalities [2].
5.3 Rituximab and proteasome inhibitors
Rituximab is a chimeric monoclonal antibody directed against CD20, which is 
found on immature and mature B cells but not on plasma cells. Following treatment 
with rituximab, B cells undergo apoptosis and lysis [55]. Most adverse events are 
first infusion effects of generally mild severity. Additionally, an increased incidence 
of infections has been described including cases of progressive multifocal leukoen-
cephalopathy [56], late onset Pneumocystis pneumonia [57] and fatal pneumococ-
cus sepsis [58].
In renal transplantation rituximab is used for desensitization of highly sensi-
tized patients or awaiting ABO-incompatible renal transplantation [59].
In case of ABMR, rituximab is used for the treatment of ABMR as a solo agent 
adjuncted to standard of care therapy [60, 61] or in some instances combined 
with bortezomib, a proteasome inhibitor causing apoptosis of mature plasma 
cells [62]. Treatment of ABMR with rituximab or bortezomib or combination 
in addition to standard therapy was in most instances partially effective on the 
short term, whereas treatment did not result in sufficient long-term graft survival 
[59–62].
The potential role of the anti-CD20 monoclonal antibody rituximab and the 
proteasome inhibitor bortezomib in decreasing the production of donor-specific 
anti-HLA antibodies and improving allograft survival in patients with antibody-
mediated rejection was recently evaluated in two randomized, controlled trials 
RITUX ERAH [63] and BORTEJECT [64], but neither trial showed clinical benefits.
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5.4 Complement inhibition
5.4.1 C5 inhibitors
Activation of the complement cascade in acute ABMR rejection has been identi-
fied as a major pathophysiological mechanism leading to allograft damage and 
dysfunction [65]. As a consequence, it has been proposed that specific inhibition 
of the recipient’s complement system of limited duration may be useful to prevent 
acute ABMR.
The anti-C5 monoclonal antibody eculizumab, which inhibits terminal comple-
ment activation, was reported to decrease the incidence of early antibody-mediated 
rejection in HLA-sensitized renal-transplant recipients [66], although it failed to 
prevent chronic antibody-mediated rejection in recipients with persistently high 
levels of donor-specific anti-HLA antibodies [67]. It was also shown that preemp-
tively usage of eculizumab following positive B-cell flow cytometric crossmatch 
transplant resulted in a reduced incidence of early ABMR from 41.0% in historical 
controls to 7.7% in eculizumab-treated patients [68].
5.4.2 C1 inhibitors
Binding of anti-HLA DSAs to complement fraction C1q, the first component 
in the activation of the complement cascade, has been associated with poor graft 
outcomes and severe phenotypes of ABMR [69]. These findings have provided 
the rationale for the use of proximal complement inhibition using C1 inhibitors 
(C1 INHs) in the treatment of ABMR. C1-INH is a serine protease inhibitor that 
inactivates both C1r and C1s and has multiple effects. Following antibody/immune 
complex activation of C1qrs, C1-INH dissociates C1r and C1s from the activated 
C1 macromolecule. This prevents proteolytic activation of C4 and C2 that form C3 
convertase, which is important in the context of C4d deposition in AMR [70]. The 
use of a plasma-derived C1 INH in the treatment of active ABMR was evaluated 
in trial of 18 kidney transplant recipients with biopsy-proven, active ABMR [71], 
who were randomly assigned to receive C1 INH or placebo as adjunct therapy to 
standard-of-care treatment with PP, IVIG, and rituximab. Although there was no 
significant difference between the groups in posttreatment renal histopathology or 
graft survival on day 20, a trend toward sustained improvement in graft function at 
day 90 was observed in the C1 INH group.
Similar findings were reported in six kidney transplant recipients with active 
ABMR that were unresponsive to treatment with PP, IVIG, and rituximab [72]. 
All patients received the C1 INH Berinert (20 units/kg on days 1, 2, and 3 and 
then twice weekly) and high-dose IVIG (2 g/kg once per month) for 6 months. At 
6 months, all patients showed an improvement in eGFR compared with baseline at 
the time of inclusion in the study. Renal allograft biopsies at 6 months revealed no 
significant change in histologic features; however, C4d deposition was observed in 
only one of six patients compared with five of six patients at baseline. In addition, 
of the six patients who were positive for a C1q-binding circulating DSA at the start 
of the study, only one had a positive DSA at 6 months.
5.5 IL-6 inhibition
The potential of proinflammatory cytokine blockade in kidney-transplant 
recipients with chronic ABMR has recently been highlighted [73]. Tocilizumab 
is a monoclonal antibody directed against the interleukin IL-6 receptor that has 
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been used for the treatment of rheumatic diseases, such as rheumatoid arthritis 
and systemic juvenile idiopathic arthritis. Recently, tocilizumab was also evalu-
ated as rescue therapy in 36 kidney transplant patients with chronic ABMR who 
failed standard-of-care treatment with IVIG and rituximab, with or without 
plasma exchange [74]. Tocilizumab was administered as 8 mg/kg monthly for 6 to 
25 months. Significant reductions in DSAs and stabilization of renal allograft func-
tion were observed at 2 years. No significant adverse events or severe adverse events 
were reported.
5.6 IdeS
IgG-degrading enzyme of Streptococcus pyogenes (IdeS) cleaves at a very specific 
amino acid sequence in the hinge region of human IgG and essentially neutralizes 
all of the IgG in the body within 4 hours of administration. There is a period of 
about 7 days during which both soluble IgG and the B cell receptor are not detect-
able, after which it begins to rebound and can reconstitute fully by day 14 [75]. In 
clinical trials ideS was used in attempting to evaluate the efficacy to desensitize 
transplant patients with a positive crossmatch, where it showed efficacy in reduc-
tion of anti-HLA antibodies before kidney transplantation in patients who were 
HLA-incompatible with their donors [76, 77]. Further studies are necessary to 
evaluate IdeS treatment as a therapeutic strategy for ABMR.
5.7 Splenectomy
A desensitization protocol may be required to avoid ABMR in patients that 
are highly sensitized, have positive crossmatch or ABO incompatibility, however 
current protocols are not always effective to prevent ABMR and in some cases fail 
to convert subjects to a negative crossmatch before transplantation. Studies have 
shown that splenectomy can be successfully performed alone or in association with 
other treatments like bortezomib, rituximab or eculizumab to overcome severe 
ABMR, resistant to standard treatment [78–82].
In an effort to spare recipients the morbidity of a splenectomy, splenic irradia-
tion in addition to other therapy may provide an effective intervention for rescuing 
and preserving allograft function [81].
6. Conclusions
Antibody-mediated rejection is an important cause of acute and chronic graft 
failure. Diagnosis of acute and chronic ABMR is based on typical histological 
hallmarks, positive C4d in peritubular capillaries and presence of donor-specific 
antibodies (DSA). Among standard of care treatment based on PP and IVIG, new 
treatment options have become available: B cell depletion (rituximab), plasma cell 
depletion (bortezomib), complement activation inhibition (c1 and c5 inhibitors), 
recently also IL-6 inhibitors and ideS. However, the high cost of novel medications 
and a lack of prospective studies evaluating their efficacy and safety limit the rou-
tine use of these agents in the treatment of ABMR in kidney transplant recipients.
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